Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, NSW, 2019, Australia.
Breast Cancer Res Treat. 2013 Sep;141(2):173-85. doi: 10.1007/s10549-013-2685-9. Epub 2013 Sep 8.
Breast cancer patients are at increased risk of sexual dysfunction. Despite this, both patients and practitioners are reluctant to initiate a conversation about sexuality. A sexual dysfunction screening tool would be helpful in clinical practice and research, however, no scale has yet been identified as a "gold standard" for this purpose. The present review aimed at evaluating the scales used in breast cancer research in respect to their psychometric properties and the extent to which they measure the DSM-5/ICD-10 aspects of sexual dysfunction. A comprehensive search of the literature was conducted for the period 1992-2013, yielding 129 studies using 30 different scales measuring sexual functioning, that were evaluated in the present review. Three scales (Arizona Sexual Experience Scale, Female Sexual Functioning Index, and Sexual Problems Scale) were identified as most closely meeting criteria for acceptable psychometric properties and incorporation of the DSM-5/ICD-10 areas of sexual dysfunction. Clinical implications for implementation of these measures are discussed as well as directions for further research.
乳腺癌患者存在性功能障碍风险增加。尽管如此,患者和医生都不愿意主动讨论与性相关的问题。性功能障碍筛查工具将有助于临床实践和研究,但目前尚未确定哪种量表可作为这一目的的“金标准”。本综述旨在评估用于乳腺癌研究的量表在测量心理计量特性和性功能障碍的 DSM-5/ICD-10 方面的程度。对 1992 年至 2013 年期间的文献进行了全面检索,共检索到 129 项研究,这些研究使用了 30 种不同的量表来测量性功能,本综述对这些量表进行了评估。有 3 种量表(亚利桑那性体验量表、女性性功能指数和性问题量表)被认为最符合心理计量特性的可接受标准,并纳入了性功能障碍的 DSM-5/ICD-10 领域。还讨论了这些措施的实施的临床意义以及进一步研究的方向。